Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Net Cash Flow (2018 - 2025)

Zevra Therapeutics' Net Cash Flow history spans 11 years, with the latest figure at $8.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 139.61% year-over-year to $8.3 million; the TTM value through Dec 2025 reached $28.6 million, up 394.23%, while the annual FY2025 figure was $28.6 million, 394.23% up from the prior year.
  • Net Cash Flow reached $8.3 million in Q4 2025 per ZVRA's latest filing, up from $6.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $71.7 million in Q1 2021 to a low of -$25.3 million in Q1 2023.
  • Average Net Cash Flow over 5 years is $2.9 million, with a median of -$680500.0 recorded in 2021.
  • Peak YoY movement for Net Cash Flow: surged 7178.38% in 2021, then crashed 3577.5% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$19.2 million in 2021, then skyrocketed by 74.68% to -$4.8 million in 2022, then surged by 88.27% to -$569000.0 in 2023, then plummeted by 3577.5% to -$20.9 million in 2024, then surged by 139.61% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Net Cash Flow are $8.3 million (Q4 2025), $6.7 million (Q3 2025), and $9.7 million (Q2 2025).